ENGLISH TRANSLATION OF JAPANESE-LANGUAGE DOCUMENT

This is a translation of the original Japanese-language document and is provided for convenience only. In all cases, the Japanese-language original shall take precedence.



December 2, 2021

To whom it may concern:

Company Name: TAIYO HOLDINGS CO., LTD.

Representative: Eiji Sato, President and CEO

(Code: 4626, listed on First Section of

Tokyo Stock Exchange)

Inquiries: Sayaka Tomioka, Executive Officer, General

Manager of Corporate Planning Department

Tel: +81-3-5953-5200 (main line)

Notice of Completion regarding Succession of Manufacturing and Marketing Approval for Four Long Listed Products

TAIYO HOLDINGS CO., LTD. (hereinafter "Taiyo Holdings") hereby announces that the succession of manufacturing and marketing approval, and the transfer of distribution in Japan from AstraZeneca K.K. (Headquarters: Kita-ku, Osaka, Japan; Representative Director and President: Stefan Woxström) to Taiyo Pharma Co., Ltd. that is a subsidiary company of Taiyo Holdings, for four long listed products, which was announced in the "Notice of Transfer of Four Long Listed Products" dated April 28, 2020, has been completed as of yesterday.

Succession of manufacturing and marketing approval, and the transfer of distribution for four products listed below were completed.

	Brand Name	Therapeutic Category	Date of Completion
1	Inderal [®] Tablets 10mg Inderal [®] Injection 2mg	Antihypertensive / angina / arrhythmia / migraine treatment Beta-blocking arrhythmia / angina treatment	July 1, 2021
2	Tenormin [®] Tablets 25 Tenormin [®] Tablets 50	Cardiac selective beta blocker	July1, 2021
3	Omepral [®] Tablets 10 Omepral [®] Tablets 20 (Excluding Omepral [®] injection 20)	Proton pump inhibitor	December 1, 2021
4	Seroken [®] Tablets 20mg Seroken L [®] Tablets 120mg	Antihypertensive / angina / arrhythmia treatment Sustained-release antihypertensive agent	December 1, 2021

Impact of this matter on the consolidated financial results for the fiscal year ending March 2022 of Taiyo Holdings has been incorporated into the financial forecast announced on November 5, 2021. If any revision of the financial forecast is required for disclosure in the future, it will be announced promptly.

References

Announced on April 28, 2020:

Notice of Transfer of Four Long Listed Products https://www.taiyo-hd.co.jp/ cms/wp-content/uploads/2020/04/20200428 01 01.pdf

End